iRhythm

iRhythm sells an ambulatory cardiac monitoring service. A physician prescribes a Zio XT patch, the patient wears it for up to 14 days, and iRhythm processes the continuous ECG data using AI algorithms. A certified cardiographic technician reviews the algorithm output and delivers a final clinical report to the prescribing physician. The firm generates revenue per test from payors including Medicare and commercial insurers.

Capital allocation is overseen by CEO Quentin Blackford and CFO Brice Bobzien. As a public company with no family-wealth backing, investment decisions focus on R&D scale and commercial expansion. The board, which includes representatives from significant institutional shareholders, approves major strategic moves.

iRhythm holds one of the largest clinically annotated ECG databases, built from over 750 million hours of heartbeat data from patients who wore the Zio patch. Each record is labeled by certified technicians using a ground-truth standard. This dataset creates a compounding advantage for training its deep-neural-network algorithms, making it difficult for a new entrant to replicate comparative diagnostic accuracy without more than a decade of data collection and clinical labeling effort.

Apple Watch and AliveCor offer consumer-driven, intermittent spot checks for atrial fibrillation. iRhythm's Zio XT and the newly cleared Zio Watch provide continuous, physician-prescribed monitoring with full-service clinical reporting. iRhythm does not market directly to consumers; its products are used under physician order and reimbursed as a medical diagnostic test, which places it in a different regulatory and reimbursement category.

Reimbursement is the single largest financial variable. In 2023, Medicare's administrative contractor Novitas maintained a national pricing determination for long-term continuous monitoring that iRhythm considers below cost. In November 2023, iRhythm filed a legal challenge against the contractor's methodology. The company has been investing in health-economic evidence studies to demonstrate that its Zio service reduces downstream costs from stroke and emergency-room visits, aiming to shift the reimbursement conversation toward value-based care.

iRhythm operates its own independent diagnostic testing facilities in Illinois and California. These are registered as clinical laboratories, and the company employs certified cardiographic technicians who review and finalize each report alongside the AI output. The service is a vertically integrated chain from device shipping to physician report delivery.

The deep-neural-network algorithms perform a first-pass classification of every heartbeat into rhythms such as atrial fibrillation, pause, tachycardia, or normal. The output classifies the full ECG strip and flags clinically significant episodes. A certified technician then reviews the flagged findings, modifies or confirms the classifications, and assembles the final report. The AI drastically reduces the time a human must spend on normal rhythms, allowing the technician to concentrate on abnormal events.